Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

1974 results about "Nervous system" patented technology

The nervous system is a highly complex part of an animal that coordinates its actions and sensory information by transmitting signals to and from different parts of its body. The nervous system detects environmental changes that impact the body, then works in tandem with the endocrine system to respond to such events. Nervous tissue first arose in wormlike organisms about 550 to 600 million years ago. In vertebrates it consists of two main parts, the central nervous system (CNS) and the peripheral nervous system (PNS). The CNS consists of the brain and spinal cord. The PNS consists mainly of nerves, which are enclosed bundles of the long fibers or axons, that connect the CNS to every other part of the body. Nerves that transmit signals from the brain are called motor or efferent nerves, while those nerves that transmit information from the body to the CNS are called sensory or afferent. Spinal nerves serve both functions and are called mixed nerves. The PNS is divided into three separate subsystems, the somatic, autonomic, and enteric nervous systems. Somatic nerves mediate voluntary movement. The autonomic nervous system is further subdivided into the sympathetic and the parasympathetic nervous systems. The sympathetic nervous system is activated in cases of emergencies to mobilize energy, while the parasympathetic nervous system is activated when organisms are in a relaxed state. The enteric nervous system functions to control the gastrointestinal system. Both autonomic and enteric nervous systems function involuntarily. Nerves that exit from the cranium are called cranial nerves while those exiting from the spinal cord are called spinal nerves.

Bupropion dosage forms with reduced food and alcohol dosing effects

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.
Owner:ANTECIP BIOVENTURES II LLC

Bupropion dosage forms with reduced food and alcohol dosing effects

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.
Owner:ANTECIP BIOVENTURES II LLC

Bupropion dosage forms with reduced food and alcohol dosing effects

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.
Owner:ANTECIP BIOVENTURES II LLC

Bupropion dosage forms with reduced food and alcohol dosing effects

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.
Owner:ANTECIP BIOVENTURES II LLC

Treatment of poor metabolizers of dextromethorphan with a combination of bupropion and dextromethorphan

Disclosed herein is a method of safely treating a nervous system condition with a combination of dextromethorphan and bupropion. This method is intended for patients having a neurological condition or a psychiatric condition, such as major depressive disorder, and a CYP2D6 poor metabolizer genotype or a CYP2D6 poor metabolizer phenotype.
Owner:ANTECIP BIOVENTURES II LLC

Neurophysiological magnetic stimulation system

A neurophysiological magnetic stimulation (NMS) method includes obtaining motor thresholds over one or both motor strips adhered to the patient's head or the equivalent anatomic region for treatment of non-brain, nervous system disorders. The method further includes applying magnetic stimulation coils to a therapeutic target region of the patient's brain, brainstem, spinal cord, or peripheral nervous system and applying NMS in increasing amplitudes as tolerated over the course of treatment.
Owner:BIED ADAM +1

Self-adaptive music intervention system based on multi-modal physiological feedback

The invention discloses a self-adaptive music intervention system based on multi-modal physiological feedback, and belongs to the technical field of monitoring and intervention of emotional states, the self-adaptive music intervention system comprises a multi-modal emotional state evaluation module and a self-adaptive music intervention module, the multi-modal emotional state evaluation module acquires multi-modal physiological information of a user, and the self-adaptive music intervention module performs music intervention on the multi-modal emotional state evaluation module; feature extraction and fusion are carried out on the multi-modal data, and the emotional state is evaluated according to the fused data; and the adaptive music intervention module generates music features matched with the current emotion according to the evaluated emotion state, the music features and preference data of the user, and selects music according to the music features to intervene the user. By the adoption of the method, the wearable forehead lobe three-lead electroencephalogram equipment and the intelligent bracelet are combined, physiological signals of the central nervous system and the autonomic nervous system are collected and analyzed in real time, music intervention is automatically adjusted, a personalized emotion adjusting scheme free of side effects is provided, and a closed-loop mental state regulation and control mechanism is formed.
Owner:BEIJING INST OF TECH

HRV-based sleep monitoring analysis method and system

The invention discloses a sleep monitoring analysis method and system based on HRV, and relates to the technical field of sleep monitoring, and the method comprises the following steps: at the beginning of monitoring, continuously recording a continuous heartbeat time interval of a sleeper at a preset initial heartbeat interval acquisition frequency for evaluating the autonomic nervous system state of the sleeper at night; the respiration data of the sleeper is acquired in real time while the heart rate data is acquired. By combining real-time respiration data and an intelligent increment control algorithm, when irregular respiration is detected, the heartbeat interval acquisition frequency is dynamically adjusted, so that the sampling precision of heart rate change is improved, fine fluctuation of a sleeper when apnea or irregular respiration occurs can be captured, and the sleep quality of the sleeper can be improved. In addition, the detection accuracy of the apnea event can be improved under high sensitivity, potential health risks can be recognized in time, more reliable data support is provided for improvement of sleep quality and early intervention, and therefore health damage caused by missing detection is effectively avoided.
Owner:GUANGXI ZHONGKE HUARUI MICROELECTRONICS CO LTD

Tree shrew epilepsy model construction method

The invention discloses a tree shrew epilepsy model construction method, which specifically comprises the following steps: (1) preparation of Phrixotoxin-1: dissolving 50 [mu] g of Phrixotoxin-1 in normal saline, fixing the volume of the normal saline to 1 ml, and preparing a solution with the concentration of 50 [mu] g / ml and the pH value of 7.4; and (2) performing intraperitoneal injection on the tree shrew by using the Phrixotoxin-1 solution prepared in the step (1), wherein the injection amount is 4 [mu] g / kg. Tree shrew is a small primate-related animal, has a high brain-body mass ratio, and has a developed nervous system and a stress system similar to human beings, so that the tree shrew model has irreplaceable advantages compared with other non-primate animal models. The excitability of the hippocampus pyramidal neurons of an epilepsy patient is increased due to the weakening of A-type potassium current (IA), and in the hippocampus and cortical neurons, the IA is only generated by a Kv4 potassium channel. According to the invention, a specific peptide inhibitor Phrixotoxin-1 of a Kv4 potassium channel is selected to prepare the tree shrew epilepsy model, and a novel preparation method of the epilepsy model is provided.
Owner:LABREAL BIOTECH KUNMING CO LTD +1

Small molecule inhibitors of repeat associated non-aug (RAN) translation and combination therapies

The present disclosure provides methods, uses, kits, and compositions comprising a compound of Formula (I), and either a second compound of Formula (I) or a compound of Formula (II). In one aspect, the methods are for treating a neurological disease associated with repeat expansions and / or RAN protein accumulation, reducing the level of one or more repeat associated non-AUG (RAN) proteins, and reducing the accumulation of RAN proteins in a subject and / or biological sample. Exemplary diseases associated with repeat expansions include, but are not limited to, amyotrophic lateral sclerosis (ALS), frontotemporal dementia, myotonic dystrophy type 1, myotonic dystrophy type 2, spinocerebellar ataxia, Alzheimer's disease, Huntington's disease, Fragile X Tremor Ataxia Syndrome, and Fragile XE syndrome.
Owner:UNIV OF FLORIDA RESEARCH FOUNDATION INC

System for providing sleep healthcare service using artificial intelligence-based brainwave entrainment and autonomic nervous system control

Disclosed is a system for providing a sleep healthcare service using brainwave entrainment and autonomous nervous system control, and the system including: a user terminal configured to set a bedtime and a wake-up time, at the bedtime, output a sleep-inducing breathing method for enhancing the parasympathetic nervous system, while emitting light of non-melatonin-suppressing wavelengths, and at the wake-up time, insert and output an Alpha-Band or Beta-Band flicker for brainwave synchronization of alpha or beta waves, and output blue light to induce arousal; and a sleep healthcare server.
Owner:LEE JANGWON +1

Intestinal function self-adaptive adjusting system based on biological feedback

The invention discloses a self-adaptive intestinal function adjusting system based on biological feedback, and relates to the technical field of intestinal function adjustment, the self-adaptive intestinal function adjusting system comprises a signal acquisition module, a data analysis module, an adjustment feedback module and a user interaction module; the signal acquisition module adopts a multi-sensor fusion algorithm and a multi-source sensor to acquire intestinal function state information; wherein the multi-source sensor comprises a pressure sensor, a peristaltic sensor and a nerve sensor. The intestinal function self-adaptive adjusting system based on biological feedback can comprehensively collect biological signals of intestinal tracts, including pressure, peristalsis, nervous system signals and chemical substance secretion signals; the multi-dimensional monitoring mode can reflect the real state of the intestinal function more accurately, the limitation of a single sensor is avoided, and a rich and accurate data basis is provided for subsequent analysis and adjustment.
Owner:JILIN UNIV FIRST HOSPITAL

Bupropion dosage forms with reduced food and alcohol dosing effects

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.
Owner:ANTECIP BIOVENTURES II LLC

Novel association of active ingredients, pharmaceutical and / or nutraceutical compositions containing it and their use in the prevention and repair of damage to the central and peripheral nervous system

PCT designated stage expiredWO2025146608A1Nervous disorderAntipyreticNervous systemNutrition
The present invention relates to a novel association or combination of active ingredients useful in the prevention and repair of neuronal damage, both centrally and peripherally. In greater detail, the present invention relates to an association or combination of i) an extract of Gastrodia elata and ii) at least one ingredient selected from the group comprising or, alternatively, consisting of citicoline, L-acetylcarnitine and, preferably, at least one vitamin of group D, and / or mixtures thereof, and / or at least one vitamin of group B, and / or mixtures thereof. Furthermore, the invention also relates to the pharmaceutical compositions and / or compositions for medical devices (Regulation (EU) 2017 / 745) and / or nutraceutical and / or food compositions comprising that association and to their use in therapy, in particular in the protection of the functionality of the nervous system and in the prevention and / or treatment of central and peripheral neuropathies.
Owner:FUTURA S R L SOVICO

Nervous system closed-loop regulation and control system based on transcranial opto-acoustic synergy

The invention provides a nervous system closed-loop regulation and control system based on transcranial opto-acoustic cooperation. The nervous system closed-loop regulation and control system is composed of EEG monitoring equipment, personal information data, an opto-acoustic cooperation system, a multi-mode large model and a psychological disease database. Aiming at a transcranial infrared light and ultrasonic co-stimulation technology of a patient, through optimization of stimulation parameters, photoacoustic bidirectional regulation and control are realized, a multi-modal large model is used as a base, multi-modal data fusion and reinforcement learning are used as technical means, closed-loop photoacoustic co-stimulation system equipment is designed, and intervention parameters are automatically optimized; an effective regulation and control method for psychological diseases is realized through a non-intrusive brain stimulation technology, and adaptive adjustment and closed-loop feedback of parameters are realized. Brain waves of a patient are detected in real time, personal information of the patient is collected, the information is integrated and transmitted into the system after evaluation, intervention is adjusted in real time according to different brain states, and feedback is utilized to adjust parameters of next intervention and stimulate the precise regulation and control process.
Owner:HEFEI INSTITUTE OF PHYSICAL SCIENCE CHINESE ACADEMY OF SCIENCES

Sleep quality analysis system based on human body HRV measurement

The invention discloses a sleep quality analysis system based on human body HRV measurement, and relates to the technical field of sleep quality, a preliminary analysis module can quickly judge the sleep quality fluctuation condition of a user through calculation of a heart rate variability factor HRV, when the HRV value exceeds a preset threshold value, the system automatically sends a sleep quality fluctuation command to a cloud platform, and the sleep quality fluctuation command is sent to the cloud platform. Therefore, the change of the sleep state is timely responded. Besides, the neural activity module analyzes the balance state of parasympathetic nerves and sympathetic nerves and constructs a neural activity proportion Jhb, the activity deviation of the nervous system of the user in the sleep state can be determined, and a reliable basis is provided for deep analysis of the sleep state. The sleep state comprehensive analysis module is further combined with the heart rate recovery ratio Xhb and the neural activity ratio Jhb, a sleep quality evaluation index Sgzs is calculated through the trained sleep quality prediction model, and quantitative evaluation of the sleep quality of the user is further achieved.
Owner:AFFILIATED HOSPITAL OF NANJING UNIV OF TRADITIONAL CHINESE MEDICINE +2

Bupropion dosage forms with reduced food and alcohol dosing effects

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.
Owner:ANTECIP BIOVENTURES II LLC

Systems and Methods for Personalized Ultrasound Neuromodulation

Disclosed herein is a system and method for implementing a personalized ultrasound neuromodulation system and methods with neural sensing of personalized electrophysiological data, guiding ultrasound targeting and dosage using such personalized data. Specific ultrasound transducer solutions are provided for various neural targets that enable the low-intensity focused ultrasound to modulate the central nervous system and peripheral nervous systems to treat a variety of neurological and mental disorders. A portable ultrasound console device, a wearable guiding apparatus and a compact solution for effectively and safely enabling point-of-care neuromodulation, e.g., home healthcare, are provided. Further methods for ultrasound waveform customization are also described to improve effectiveness of ultrasound neuromodulation.
Owner:CARNEGIE MELLON UNIV

Systems and methods for imaging and modulating the nervous system using an ultrasound-based brain-computer interface

Devices, methods, and systems related to ultrasound imaging or modulating of the nervous system are described. The devices may comprise, for example, one or more ultrasound transducers, wherein an ultrasound transducer from the one or more ultrasound transducers can comprise an implantable ultrasound transducer, wherein the implantable ultrasound transducer can comprise a sonolucent window. The methods and systems may also comprise, for example, a method of imaging and / or modulating the nervous system of a subject using the one or more ultrasound transducers. The method of imaging and / or modulating the nervous system of the subject can be based on a closed-loop operation, wherein an iteration of the imaging and / or the modulating of the nervous system is based on a prior iteration. The closed-loop operation can comprise ultrasound imaging and ultrasound-based modulating or electrophysiological modulating. The methods can further comprise methods of analyzing ultrasound data, such as via an artificial neural network.
Owner:FOREST NEUROTECH LLC

Anesthesia monitoring system

PendingUS20250009292A1ElectrotherapySensorsNervous systemRegional anaesthesia
A method for determining an effect of anesthesia in a subject, including:stimulating a body of a subject at one or more stimulation sites, wherein the subject is under regional anesthesia;measuring a response of the subject to the stimulation, wherein said response passes through a nervous system of the subject;determining an effect of the regional anesthesia on the subject body based on results of the measuring.
Owner:IZAKSON MASIE ZVI

Method and system for evaluating and training attention of children

The invention relates to a child attention evaluation and training method and system, and the method comprises the steps: obtaining a brain wave mode, an eyeball movement track, an emotion activation level and autonomic nervous system function data of a child in real time, and generating multi-dimensional biological signal data; based on the multi-dimensional biological signal data, generating evaluation task data; generating dynamic task parameters according to biological signal data and behavior performance data in the evaluation task data; generating an attention feedback signal based on the dynamic task parameters; according to the attention feedback signal, a training task integrating work memory, suppression control and cognitive flexibility is constructed, and cognitive function training data is generated; and based on the cognitive function training data, synchronously sharing the attention performance data of the children to the parent terminal and the teacher terminal, generating life situation intervention suggestions, and iteratively optimizing evaluation parameters according to a long-term effect evaluation result. Therefore, the accuracy of children attention evaluation and training can be improved.
Owner:NANFANG HOSPITAL OF SOUTHERN MEDICAL UNIV

Advantageous benzofuran compositions for mental disorders or enhancement

Pharmaceutically active benzofuran compositions for the treatment of mental disorders or for mental enhancement, including for entactogenic therapy. The present invention also includes benzofuran compounds, compositions, and methods for generally modulating central nervous system activity and treating central nervous system disorders.
Owner:TACTOGEN INC

Treatment of poor metabolizers of dextromethorphan with a combination of bupropion and dextromethorphan

Disclosed herein is a method of safely treating a nervous system condition with a combination of dextromethorphan and bupropion. This method is intended for patients having a neurological condition or a psychiatric condition, such as major depressive disorder, and a CYP2D6 poor metabolizer genotype or a CYP2D6 poor metabolizer phenotype.
Owner:ANTECIP BIOVENTURES II LLC

Lactobacillus reuteri CCFM1288 for relieving depressive mood and application of lactobacillus reuteri CCFM1288

PendingCN119331766AIncrease alpha-diversitymaintain steady stateMilk preparationNervous disorderSerotoninNervous system
The invention discloses lactobacillus reuteri CCFM1288 for relieving depressive mood and application of the lactobacillus reuteri CCFM1288, and belongs to the technical field of microorganisms. The lactobacillus reuteri CCFM1288 has the tryptophan metabolism capability, and can survive for 7 days in the intestinal tract; after the lactobacillus reuteri CCFM1288 intervenes a depressive mouse, anxiety-like and depression-like behaviors of the mouse can be obviously relieved, flora alpha-diversity is improved, intestinal symbiotic bacteria are promoted to secrete indole substances, intestinal homeostasis is maintained, hypothalamic-pituitary-adrenal axis hyperfunction is relieved, dopamine and serotonin neurotransmitter nervous system functions are improved, and the effect of preventing and treating depression is achieved. The neurotransmitter release is promoted, and the anti-depression effect is achieved. In clinical tests, intervention of Lactobacillus reuteri CCFM1288 can significantly improve the depressive symptom of MDD patients, and a new safe alleviation approach is provided for depression treatment.
Owner:JIANGNAN UNIV

Apparatus for treating neurological disorders by electrostimulation and method for processing neural signals collected by the said apparatus

Disclosed herein are apparatuses and methods for treating neurological disorders by electro-stimulation. The apparatus (10) for treating neurological disorders includes at least one electrode (12) implantable in the brain of a patient, and a processing and stimulation device (14) connected to the at least one electrode (12). The processing and stimulation device (14) may include a stimulation module (16) configured to generate a stimulation signal to be sent to the at least one electrode (12), and an acquisition module (20) that measures cerebral activity coming from the brain of the patient. The acquisition module (20) may have a front-end block (27) configured to amplify the potential difference of its input signals (V1a, V2a) and to filter a stimulus artifact and may include a multi-stage fully-differential switched capacitor circuit (e.g., an integrated circuit) configured for discrete-time signal processing.
Owner:NEWRONIKA

Remote monitoring system for nervous system based on intelligent wearable device

The invention relates to the technical field of medical equipment, in particular to a nervous system remote monitoring system based on intelligent wearable equipment, which comprises a sensor module, a data processing module, a real-time monitoring module, a remote transmission module, a feedback and intervention module, a data storage and analysis module and a user interface module. The sensor module collects nervous system signals of a human body, the data processing module conducts denoising, feature extraction and mode recognition on the nervous system signals and generates warning signals, the remote transmission module transmits data to a remote server or a medical terminal, and the feedback and intervention module provides health suggestions and triggers intervention measures according to monitoring results. The data storage and analysis module performs comprehensive analysis on long-term monitoring data by using a big data analysis technology, and the user interface module provides visual display through a smart phone or wearable equipment. According to the system, real-time monitoring, remote diagnosis and personalized health management of the nervous system are realized, and the system has wide clinical application value.
Owner:HEILONGJIANG PROVINCIAL INST FOR INFECTIOUS DISEASE CONTROL & PREVENTION

Methods and devices for photobiomodulation

Systems and methods are described for treatment of neurological conditions in which transcranial illumination using infrared, near-infrared and / or red wavelengths of light are delivered into the brain of a patient using a portable head wearable device. Systems and methods are also described to deliver light to patient tissues for photobiomodulation, particularly through the patient's mouth.
Owner:JELIKALITE LLC

Physical index monitoring system for patient in neurology department

The invention discloses a neurology patient body index monitoring system, and particularly relates to the technical field of body monitoring. The environment interaction and adaptation module is used for monitoring and adjusting the surrounding environment of a patient to optimize the health state of the nervous system; the emotion and psychological state monitoring module is used for evaluating the emotion and psychological state of the patient in real time by utilizing an advanced sensing technology and data analysis; and the cognitive function and learning support module is used for monitoring and promoting the cognitive function of the patient to improve neuroplasticity and cognitive ability through interaction and training. By integrating the environment interaction and adaptation module, the emotion and psychological state monitoring module, the cognitive function and learning support module and the comprehensive health ecosystem module, intelligent adjustment of the surrounding environment of a patient, real-time monitoring of the emotion and psychological state, improvement of the cognitive function and comprehensive integration of health resources are achieved; the system optimizes the environmental comfort through intelligent illumination, noise monitoring and air quality adjustment.
Owner:QIANDONGNAN MIAO & DONG AUTONOMOUS PREFECTURE PEOPLES HOSPITAL

Intelligent magnetic field nerve regulation rehabilitation system

The invention relates to the technical field of neuromodulation and rehabilitation treatment, and discloses an intelligent magnetic field neuromodulation rehabilitation system, which comprises a signal acquisition and feature extraction module for acquiring brain signals of a patient and extracting multi-scale variables including microscopic neuron membrane potential, mesoscopic brain region synchronism and macroscopic cognitive state; the magnetic field adjusting module is used for generating and outputting magnetic field stimulation signals according to the optimization result, and the magnetic field stimulation signals comprise frequency, intensity and waveform parameters of a magnetic field; the dynamic optimization module is used for calculating an optimal path of the magnetic field stimulation signal based on the input multi-scale variable and the constraint condition; and the closed-loop feedback control module is used for receiving the real-time brain signal to update the system state and adjusting the parameters of the magnetic field stimulation signal based on feedback. Through multi-scale modeling, real-time feedback regulation and control and man-machine interaction technologies, precise regulation and control, efficient adaptability and visual clinical operation effects of the nervous system are achieved.
Owner:HENAN ANYTHING TECH DEV CO LTD

Apparatus and method for reduction of neurological movement disorder symptoms using wearable device

PCT designated stage expiredWO2025038457A1Vibration massageStimulus patternThird party
A multimodal wearable band which uses mechanical vibrations to stimulate sensory neurons in the wrist or ankle in order to reduce the severity of tremors, rigidity, involuntary muscle contractions, and bradykinesia caused by neurological movement disorders and to free users from freezing induced by movement disorders. The device uses sensors to provide output used by a processing unit to determine the optimal stimulation pattern for each user and to determine when stimulation is necessary, and then uses one or more vibration motors to accordingly stimulate the user's neurological pathways to lessen the severity of a user's symptoms. The device can also be adapted to integrate with 3rd party devices.
Owner:ENCORA INC